晚期胃癌系列-ML17032研究报告.ppt

* XP and FP were similar in terms of the percentage of patients with treatment-related AEs (all grades) [1]. AEs were reported in nearly all patients (96% of subjects) in both treatment arms and most were treatment-related. Characteristic of fluoropyrimidine-based therapy, GI AEs were among the most frequent AEs in both treatment groups. All-grade HFS was more frequent with XP than with FP (22% vs 4%) but led to discontinuation of trial treatment in only one?patient (1%) in the XP group. Overall, the safety profile of 希罗达-based therapy is similar to that of infusional 5-FU. 1. Kang Y-K et a